Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

China flag China · Delayed Price · Currency is CNY
32.72
+2.58 (8.56%)
Feb 4, 2026, 3:04 PM CST
46.86%
Market Cap4.28B +47.3%
Revenue (ttm)619.88M +0.8%
Net Income-187.70M
EPS-1.45
Shares Out130.89M
PE Ration/a
Forward PEn/a
Dividend0.13 (0.43%)
Ex-Dividend Daten/a
Volume14,441,000
Average Volume9,519,220
Open30.80
Previous Close30.14
Day's Range29.88 - 33.00
52-Week Range19.00 - 61.76
Beta0.20
RSI58.63
Earnings DateApr 24, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Epramine for Injection; Mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pe... [Read more]

Sector Healthcare
Founded 1992
Employees 1,309
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300683
Full Company Profile

Financial Performance

In 2024, SHE:300683's revenue was 648.97 million, an increase of 7.75% compared to the previous year's 602.28 million. Losses were -69.35 million, -42.60% less than in 2023.

Financial Statements